Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
June 21, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
June 08, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
March 17, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022 07:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
ASCEND Unveils Visionary Agenda, Inspiring Speakers, and Community Spirit
September 30, 2021 13:15 ET
|
AIAA
RESTON, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- ASCEND, the interdisciplinary community focused on building humanity’s off-world future faster, today unveiled its six-day agenda packed with hundreds...
“Fast Forward,” ASCEND’s New On-Demand Interview Series, Envisions Our Off-World Future
September 07, 2021 12:15 ET
|
AIAA
RESTON, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ASCEND, the only community on the planet dedicated to building humanity’s off-world future faster, today premiered “Fast Forward” – an original...
Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021
August 04, 2021 11:50 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
June 10, 2021 08:00 ET
|
HiberCell
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...
COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 08, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
LONDON, June 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
June 03, 2021 09:27 ET
|
COMPASS Pathfinder Ltd.
LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...